Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Melanoma and other skin tumours

3540 - Phase II multicenter, single arm, open label study of Nivolumab in combination with Ipilimumab in untreated patients with metastatic uveal melanoma. GEM1402.NCT02626962


20 Oct 2018


Poster Discussion session - Melanoma and other skin tumours



Tumour Site



Josep Maria Piulats Rodriguez


Annals of Oncology (2018) 29 (suppl_8): viii442-viii466. 10.1093/annonc/mdy289


J.M. Piulats Rodriguez1, L. De La Cruz Merino2, E. Espinosa3, L. Alonso Carrión4, S. Martin Algarra5, R. López-Castro6, M.T. Curiel García7, D. Rodriguez Abreu8, A.J. Rullan Iriarte9, A. Berrocal Jaime10

Author affiliations

  • 1 Medical Oncology, Institut Catala d'Oncologia (ICO), 08907 - Barcelona/ES
  • 2 Oncology, Hospital Universitario Virgen Macarena, 41003 - Sevilla/ES
  • 3 Oncology, Hospital Universitario La Paz, 28046 - Madrid/ES
  • 4 Oncology, ljalonso@uma.es, 29010 - Málaga/ES
  • 5 Oncology, Clínica Universitaria de Navarra, 31008 - Navarra/ES
  • 6 Medical Oncology, Hospital Universitario Clínico de Valladolid, Valladolid/ES
  • 7 Oncology, Hospital Universitario Clínico de Santiago, 15706 - Santiago de Compostela/ES
  • 8 Oncology, Hospital Insular de Canarias, 35016 - Las Palmas de Gran Canarias/ES
  • 9 Oncology, Institut Catala de Oncologia, 8907 - Barcelona/ES
  • 10 Medical Oncology, Hospital General Universitario Valencia, 46018 - Valencia/ES


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3540


Uveal melanoma (UM) accounts for 0.1% of cancer-related deaths. Liver disease is the most common finding. Life expectancy is reduced (<9 months) and chemotherapy seems not to improve overall survival (OS). Nivolumab plus ipilimumab (NIVO+IPI) has showed efficacy in metastatic skin melanoma, but to date no evidence on metastatic UM (MUM) is available.


GEM1402 is a phase-II, single-arm trial, leaded by the Spanish Melanoma Group (GEM) on NIVO+IPI in 50 untreated pts with MUM and ECOG-PS 0/1, recruited in 10 Spanish Sites. NIVO (1mg/kg, q3wk) and IPI (3mg/kg q3wk) were administered during 4 inductions, followed by NIVO (3mg/kg q2wk) until progressive disease (PD), toxicity or withdrawal. OS, progression free survival (PFS), overall response rate (ORR) per RECIST 1.1 (q6wk), and safety were evaluated. Intention to treat analysis includes pts with PD at first radiological evaluation. All pts receiving at least one dose of study treatment were evaluable for safety. Final data is disclosed.


A total of 50 of 52 pts enrolled from April 2016 to May 2017 were analyzed. Median age 59 (26-84), 48% male, liver M1 in 76% pts, extra-liver M1 in 56% pts, 32% elevated LDH. 33 pts completed 2 cycles and 7 pts stopped after 1 dose (6 PD, 1 toxicity). Treatment-related adverse events were reported in 46 pts and treatment discontinuation in 9 pts. G ≥ 3 toxicities were reported in 27 pts (54%): transaminitis, dermatological, hepatitis, diarrhea, neurological, anemia, thyroiditis, hyperthyroidism, hypophysitis and hyponatremia. All G3/4 were resolved following the related guidelines. A G5 acute thyroiditis related to NIVO+IPI was reported. ORR was 6/50(12%)(95%CI 3-21), disease stabilization in 26/50(52%) and Disease Control Rate was 64% (95%CI 50.7-77.3). With a median follow-up of 7.06m, PFS was 3.27m. Median OS was 12.7 months.


Combination of NIVO+IPI is feasible in terms of efficacy and toxicity for MUM that merit further investigation.

Clinical trial identification


Legal entity responsible for the study

Grupo Español Multidisciplinar de Melanoma.


Bristol-Myers Squibb (BMS).

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.